MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
1of 74 Template 16.2A Phase 4, Randomized, Double -blind, Placebo -controlled Study 
to Evaluate the Safety of 2 New 6:2 Influenza V irus Reassortants 
in Adults
Sponsor Protocol Number: D2560C00015
Application Number:
Investigational Product: Influenza Virus Vaccine, Bivalent, Subty pe A/H3N2, Ty pe B, 
Live, Col d Adapted
Sponsor: MedImmune, LLC, a wholly owned subsidiary o f AstraZeneca 
One MedImmune Way
Gaithersburg, MD 20878, USA
Medical Monitor:
Protocol History, Date : Original  Protocol , 27Mar2018

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
2of 74 Template 16.2PROTOCOL SYNOPSIS
TITLE
A Phase 4, Randomized, Double -blind, Placebo -controlled Study to Evaluate the Safety of 2 New 6:2 Influenza 
Virus Reassortant s in Adults
HYPOTHESIS
The hy pothesis for this study is that 2 new live attenuated influenza strains based on Ann Arbor master donor 
viruses (MDVs) ( Maassab, 1968 ; Maassab et al, 1985 ) will have a safety and tolerability profile consistent with 
previously evaluated strains produced using this technology.
OBJECTIVE
The objective of this study is to assess the safety of a bivalent influenza virus vaccine of 2 new 6:2 influenza 
virus reassortants in healthy adults prior to the release of the quadrivalent vaccine (FluMist®Quadrivalent) 
containing them.
STUDY ENDPOINTS
The primary endpoint of this study is fever (Days 1 through 8), defined as oral temperature ≥101°F.
The secondary end points of this study are:
1.Solicited symptoms that occur within 7 days after vaccination (Days 1 -8)
2.Adverse events (AEs) that occur within 7 days after vaccination (Days 1 -8)
3.Solicited symptoms that occur within 14 days after vaccination (Days 1 -15)
4.AEs that occur within 14 days after vaccination (Days 1 -15)
5.Serious adverse events (SAEs) that occur within 28 days after vaccination (Days 1 -29) 
6.New onset chronic diseases (NOCDs) that occur within 28 days after vaccination (Days 1-29) 
7.SAE s that occur within 180 days after vaccination (Days 1-181)
8.NOCDs that occur within 180 days after vaccination (Days 1 -181)
STUDY DESIGN   
This prospective, randomized, double -blind, placebo -controlled release study will enroll approximately 
300health y adults 18 through 49 years of age (not yet reached their 50th birthday). Eligible subjects will be 
randomly  assigned in a 4:1 fashion to receive a single dose of bivalent vaccine or placebo by intranasal spray. 
This study will be conducted at 2 sites in the United States of America (USA). Randomization will be stratified 
by site.
Each subject will receive one dose of investigational product on Day 1. Subjects will be followed through 
180days after receipt of investigational product.
TARGET SUBJECT POPUL ATION
The subjects in this study will be healthy adults 18 through 49 years of age (not yet reached their 50th birthday).
INVESTIGATIONAL PRODUCT, DOSAGE, AND MODE OF ADMINISTRATION
Eligible subjects will be randomly assigned in a 4:1 ratio to receive a single dose of either bivalent vaccine 
(240 subjects) or placebo (60 subjects) by intranasal spray on Day 1.
STATISTICAL ANALYSIS PLAN
General Considerations
Data will be provided in data listings sorted by treatment group and subject identification numb er. Tabular 
summaries will be presented by treatment group. Categorical data will be summarized by the number and 
percentage of subjects in each category. Continuous variables will be summarized by descriptive statistics, 
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
3of 74 Template 16.2including mean, standard deviation , median, minimum, and maximum. Confidence intervals (CIs) will be 
two-sided, unless otherwise stated.
The intent -to-treat (ITT) population is defined as all subjects that are randomized and treated with 
investigational product. All analyses will be perfor med on the ITT population unless otherwise specified.
Sample Size and Power Calculations
Based on the solicited event rates following FluMist®and placebo vaccination in healthy adults 18 to 64 years 
of age in Study AV009, the currently proposed study wit h 300 evaluable subjects (240 bivalent vaccine and 
60placebo recipients) will provide at least 98% power to rule out a rate increase of 5 percentage points 
assuming the true difference between the treatment groups is zero and the true fever rate is ≤ 1%. Power is lower 
if the true difference is different from zero. For example, if the true fever rates are 2% and 1% in vaccine and 
placebo recipients, respectively, the power will be 77%. For other solicited symptoms with 300 evaluable 
subjects (240 bivalent vaccine and 60 placebo recipients), the currently proposed study provides at least 87% 
power to rule out a 20 percentage point increase, assuming the true difference between the 2 treatment groups is 
zero. Power is lower if the true difference is greater t han zero.
Assessment of Endpoints
The primary endpoint of this study is fever (Days 1 through 8), defined as oral temperature ≥101°F. 
Comparison of the rate of fever between the 2 treatment groups will be based on the upper limit of the two -sided 
95% exac t CIs for the rate increase (bivalent vaccine minus placebo) evaluated against the pre -specified 
equivalence criterion of 5 percentage points.
This corresponds to the null hypothesis of:
H0:  Rate difference ≥ 5 percentage points.
The alternative hypothes is is:
HA:  Rate difference < 5 percentage points.
A two -sided 95% CI will be constructed using the exact method based on the score statistic proposed by 
(Chanand Zhang, 1999 ). This method computes the lower and upper c onfidence limits by inverting 2 separate 
one-sided tests of half the nominal Type I error rate. Its test statistic is based on the score statistic that is 
computed as the observed difference of the 2 binomial event rates minus the hypothesized value of the rate 
difference (observed rate difference) divided by the standard error of this difference under the alternative 
hypothesis. This test assures that the Type I error does not exceed the pre -specified level. Due to discreteness 
when the sample size is rela tively small compared to the expected event rate, the associated Type I error rate 
could be quite conservative, that is, smaller than the pre -specified level.
Secondary endpoints of the study include other reported solicited symptoms and AEs that occur wit hin 7 day s 
after vaccination (Days 1 through 8), and all solicited symptoms and AEs that occur within 14 days after 
vaccination (Days 1 through 15). Additional secondary endpoints include SAEs and NOCDs that occur within 
28 days after vaccination (Days 1 t hrough 29) and within 180 days after vaccination (Days 1 through 181).
Fever will be summarized according to the following thresholds:
• Oral > 100°F
• Oral ≥ 101°F
• Oral > 102°F
• Oral > 103°F
A secondary analysis comparing rates of other solicited symptoms (Day s 1 through 8) between the 2 treatment 
groups will be performed. Exact two -sided 95% CIs ( Chan and Zhang, 1999 ) on the rate difference (bivalent 
vaccine minus placebo) will be constructed. There are no pre -specified e quivalence criteria for the secondary 
analy ses.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
4of 74 Template 16.2The number of days of solicited symptoms and the proportion of subjects experiencing each event by study day 
will be presented without formal statistical comparison. The distribution of the number of days wit h each 
individual event will also be summarized without formal statistical comparison. The proportion of subjects using 
antipy retic and analgesic agents within 7 days after vaccination (Days 1 through 8) and 14 days after vaccination 
(Day s 1 through 15) wi ll be summarized by treatment group.
Interim Analysis
A safety analysis will be conducted after all subjects have been followed through Day 15 and all data through at 
least Day 8 are locked. The analysis for Days 1 through 15 will include the primary endpo int of this study (fever 
for Day s 1 through 8, defined as oral temperature ≥101°F), as well as analysis of safety data (solicited 
symptoms and AEs), and antipyretics and analgesic use reported within 7 days and within 14 days after dosing. 
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
5of 74 Template 16.2TABLE OF  CONT ENTS
PROTOCOL SYNOPSIS .................................................................................................. 2
1 INTRODUCTION ........................................................................................ 10
1.1 Disease Background ..................................................................................... 10
1.2 FluMist Quadrivalent Background ................................................................ 11
1.3 Summary  of Nonclinical Experience ............................................................. 11
1.4 Summary  of Clinical Experience ................................................................... 13
1.5 Rationale for Conducting the Study .............................................................. 14
1.6 Research Hypothesis ..................................................................................... 14
2 OBJECTIVE ................................................................................................. 14
2.1 Primary Object ive......................................................................................... 14
2.2 Study Endpo ints............................................................................................ 15
2.2.1 Primary Endpo int.......................................................................................... 15
2.2.2 Secondary  Endpo ints.................................................................................... 15
3 STUDY DESIGN ......................................................................................... 15
3.1 Descript ion of the Study ............................................................................... 15
3.1.1 Overview.......... ............................................................................................ 15
3.1.2 Treatment Regimen ....................................................................................... 16
3.2 Study  Design and Dose Rat ionale................................................................. 16
3.2.1 Dose Rati onale .............................................................................................. 16
3.2.2 Rationale for Study  Popul ation..................................................................... 16
3.2.3 Rationale for Endpoints ................................................................................ 17
4 MATERIALS AND METHOD S.................................................................. 17
4.1 Subjects ........................................................................................................ 17
4.1.1 Number of Subjects ...................................................................................... 17
4.1.2 Inclusio n Cri teria.......................................................................................... 17
4.1.3 Exclusio n Cri teria......................................................................................... 18
4.1.4 Subject Enrollment and Rando mizat ion........................................................ 20
4.1.5 Withdrawal fro m the Study ........................................................................... 20
4.1.6 Replacement of Subjects ............................................................................... 20
4.1.7 Withdrawal o f Informed Consent for Data .................................................... 21
4.2 Schedule of Study  Procedures ....................................................................... 21
4.2.1 Screening Visit (Visit 1) ............................................................................... 23
4.2.2 Treatment Period (Visit 2) ............................................................................ 23
4.2.3 Follow-up Peri od (Unscheduled Visit and Telephone Contacts) .................... 24
4.2.3.1 Unscheduled Visit, Day s 2 to 15 for Si gnificant Febrile Illness ..................... 24
4.2.3.2 Telephone Contact, Days 2 to 15 ................................
................................... 24
4.2.3.3 Telephone Contact, Days 31, 61, 91, 121, 151 (+ 7 day s).............................. 24
4.2.3.4 Telephone Contact, Day  181 (+ 14 days): Last Follow -up Con tact and Study  
Terminat ion.................................................................................................. 24
4.3 Descript ion of Study Procedures ................................................................... 24
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
6of 74 Template 16.24.3.1 Medical History  and Physical Examinat ion, Hei ght, Wei ght, and 
Temperature .................................................................................................. 24
4.3.2 Clinical Laboratory  Tests .............................................................................. 24
4.4 Invest igational Products ................................................................................ 25
4.4.1 Ident ity of Invest igational Products ............................................................... 25
4.4.1.1 Invest igational Product Inspect ion................................................................ 26
4.4.1.2 Treatment Administration ............................................................................. 26
4.4.1.3 Moni toring of Dose Administration .............................................................. 26
4.4.1.4 Reporting Product Complaints ...................................................................... 26
4.4.2 Addit ional Study  Medicat ions....................................................................... 27
4.4.3 Labeling………………. ............................................................................... 27
4.4.4 Storage…………………. .............................................................................. 27
4.4.5 Treatment Compliance .................................................................................. 27
4.4.6 Accountabilit y.............................................................................................. 27
4.5 Treatment Assignment and Blinding ............................................................. 28
4.5.1 Methods for Assigning Treatment Groups ..................................................... 28
4.5.2 Methods for Ensuring Blinding ..................................................................... 28
4.5.3 Methods for Unblinding ................................................................................ 28
4.5.3.1 Unblinding in the Event of a Medical Emergency ......................................... 28
4.5.3.2 Unblinding for Interim Analysis ................................................................... 29
4.6 Restrictions During the Study  and Conco mitant Treatm ent(s) ....................... 29
4.6.1 Permi tted Concomitant Medications ............................................................. 29
4.6.2 Prohibited Conco mitant Medi cations............................................................ 29
4.7 Statistical Evaluat ion.................................................................................... 30
4.7.1 General Considerations ................................................................................. 30
4.7.2 Sample Si ze and Power Calculations ............................................................. 30
4.7.3 Endpoints............................ ........................................................................... 32
4.7.3.1 Primary Endpo int.......................................................................................... 32
4.7.3.2 Secondary  Endpo ints.................................................................................... 33
4.7.4 Interim Analysis ........................................................................................... 34
5 ASSESSMENT OF SAFETY ....................................................................... 34
5.1 Definit ion of Adverse Events ........................................................................ 34
5.2 Definit ion of Serious Adverse Events ........................................................... 35
5.3 Definit ion of Solicited Symptoms ................................................................. 35
5.4 Definit ion of New Onset Chronic Diseases ................................................... 36
5.5 Recording of Adverse Events ........................................................................ 36
5.5.1 Time Period for Collect ion of Adverse Events .............................................. 36
5.5.2 Recording of So licited Symptoms ................................................................. 36
5.5.3 Follow-up of  Unreso lved Adverse Events ..................................................... 37
5.6 Reporting of Serious Adverse Events ............................................................ 37
5.7 Other Events Requiring Immediate Reporting ............................................... 38
5.7.1 Overdose…………………… ........................................................................ 38
5.7.2 Pregnancy………. ........................................................................................ 38
5.7.2.1 Maternal Exposure ........................................................................................ 38
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
7of 74 Template 16.26 STUDY AND DATA MANAGEMENT ....................................................... 39
6.1 Training of Study  Site Personnel ................................................................... 39
6.2 Moni toring of the Study ................................................................................ 39
6.2.1 Source Data .................................................................................................. 39
6.2.2 Study  Agreements ......................................................................................... 39
6.2.3 Archiving of Study  Docum ents..................................................................... 40
6.3 Study  Timetable and End of Study ................................................................ 40
6.4 Data Management ......................................................................................... 40
6.5 Medical Monitor Coverage ........................................................................... 40
7 ETHICAL AND REGULATO RY REQUIREMENTS .................................. 41
7.1 Ethical Conduct of the Study ......................................................................... 41
7.2 Subject Data Protection ................................................................................. 41
7.3 Ethics and Regulatory  Review ...................................................................... 41
7.4 Inform ed Consent ......................................................................................... 42
7.5 Changes to the Protocol and Informed Consent Form .................................... 42
7.6 Audits and I nspect ions.................................................................................. 43
8 REFERENCES ............................................................................................. 44
LIST OF IN -TEXT TABLES
Table 1 Highly Effective Methods of Contraception ......................................... 18
Table 2 Schedule of Study  Procedures .............................................................. 22
Table 3 Ident ification of Invest igational Products ............................................. 25
Table 4 Summary  of Solici ted Events (Day s 0 Through 7) in Study  AV009.....30
Table 5 Power to Show Similar Fever Rates for N = 300 Subjects .................... 31
Table 6 Power For Secondary  Endpo ints.......................................................... 32
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
8of 74 Template 16.2LIST OF IN -TEXT FIG URES
Figure 1 Study  Flow Diagram ............................................................................ 16
LIST OF APPENDICES
Appendix 1 Signature of Principal Investigator ....................................................... 45
Appendix 2 Addit ional Safet y Guidance ................................................................. 47
Appendix 3 FluMist®Quadrivalent Package Insert ................................................. 49
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
9of 74 Template 16.2List of Abbreviations
Abbreviation or 
Specialized TermDefinition
AE adverse event
att attenuated
BD Becton Dickinson (Accuspray™)
BFS blow fill seal
ca cold-adapted
CBER Center for Biologics Evaluation and Research
CI confidence interval
eCRF electronic case report form
EDC electronic data capture
GMP Good Manufacturing Practice
hCG human chorionic gonadotropin
HIPAA Health Insurance Portability and Accountability Act
ICH International Council for Harmonisation
IRB Institutio nal Review Board
ITT intent -to-treat
IWRS interactive web response system
MDV Master Donor Virus
MVS Master Virus Seed
NOCD new onset chronic disease
SAE serious adverse event
SID subject identification
ts temperature -sensitive
USA United States of America
VRBPAC Vaccines and Related Biological Products Advisor y Committee
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
10of 74 Template 16.21 INTRODUCTION
1.1 Disease Background
FluMist®Quadrivalent i s an intranasally administered influenza vaccine that was developed as 
a successor vaccine to FluMist®seasonal trivalent influenza vaccine. FluMist contained 3 live 
reassortant strains of influenza virus, includin g 2 type A strains (H1N1 and H3N2) and 
1typeB strain. Developed to address the issues of cocirculat ion of B strains fro m 2 lineages 
and mismatch between the single B strain lineage included in seasonal influenza vaccines and 
the predominant ly circulating strain, FluMist Quadrivalent contains 4 live reassortant strains 
of influenza virus: A/H1N1, A/H3N2, and 2 ty pe B strains. FluMist Quadrivalent contains 
biologically  active com ponents that are i dentical to those in FluMist except that a fourth strain 
is blended into the final vaccine. The 2 vaccines are produced by the same manufacturing 
process, beginning with the preparation of the Master Virus Seed (MVS) for each strain. The 
MVS for each strain contains 6 gene segments from the co ld-adapted ( ca) Master Donor Virus 
(MDV) and the hemagglut
inin and neuraminidase gene segments fro m a wild -type vi rus 
isolate and is called a 6:2 reassortant. In the United States of America (USA), the strains used 
for influenza vaccines each season are recommended annually  by the Vaccines and Related 
Biological Products Advisory  Commi ttee (VRBPAC) to the Center for Biologics Evaluat ion 
and Research (CBER). The wild -type strains chosen for a given year are then provided to 
influenza vaccine manufacturers by  either CBER or the Cen ters f or Di sease Control  and 
Prevent ion for preparation of vaccine. 
Num erous safet y tests are conducted for FluMist Quadrivalent during the manufacturing 
process of the vaccine including tests for absence of microorganisms; tests for absence of 
advent itious agents; and confirmat ion of the vaccine virus phenoty pe (col d adaptati on, 
temperature sensit ivity, and attenuat ion). Addit ionally , after new reassortants are m ade to 
match selected strains for the upcoming influenza season, their safet y profile is evaluated in a 
clinical study  in adults in order to provide further safet y data pri or to the rel ease of the 
commercial vaccine.
The design of this clinical study will ensure that any  new influenza vaccine virus reassortant 
has sufficient attenuation in humans, as dem onstrated by  the l ow incidence of fever ≥ 101°F 
(oral or equivalent). In previous clinical studies, the rate of fever in adults following 
administration of FluMist has been low and similar in both vaccinees and placebo recipients. 
For example, in Study AV009 conducted in 4,561 healt hy adults 18 through 64 y ears of age 
(3,041 FluMist recipients and 1,520 placebo recipients), fever ≥ 101°F occurred in 0.57% and 
0.60% of FluMist and placebo recipients, respectively. In Study  MI-CP185 conducted in 
1,800 a dults 18 through 49 y ears of age (1,197 FluMist Quadrivalent recipients and 
597FluMist reci pients) fever > 101.3°F occurred in 0.8% and 0.3% of FluMist Quadrivalent 
and FluMist recipients, respectively. Thus, in a placebo -controlled study  in healt hy adult s to 
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
11of 74 Template 16.2evaluate new strains, vaccine recipients would be expected to develop temperature increases at 
rates similar to th ose of  placebo reci pients fo llowing vaccinat ion.
1.2 FluMist Quadrivalent Background
FluMist Quadrivalent is briefly described below. Refer t o the current package insert for details 
(Appendix 3). 
The active agents of FluMist Quadrivalent consist of 2 ca, tem perature -sensit ive (ts), 
attenuated ( att) reassortant influenza strains of ty pe A (i e, A/H1N1 and A/H3N2), 1 ca/ts/att
reassortant influenza strain of ty pe B-Victori a, and 1 ca/ts/att reassortant influenza strain of 
type B-Yamagata. The ty pes A and B MDVs, from which the reassorta nt strains are derived, 
were adapted to grow in primary chick kidney cells at 25°C by  sequential  passage at 
progressively lower temperatures. During the process of co ld adaptation, each virus acquired 
mutati ons that conferred unique bio logical  phenotypes o f cold adaptati on, tem perature 
sensit ivity, and attenuati on, which dist inguish these viruses fro m wild-type influenza viruses.
While the commercial formulat ion of FluMist Quadrivalent can be stored at 2°C to 8°C, the 
vaccine to be used in this study
 will r equire storage in a freezer. 
1.3 Summary of Nonclinical Experience
A number of nonclinical studies o f FluMist have been conducted in ferrets, as the ferret has 
been proven to be a good model for studying influenza. 
The nonclinical program for FluMist Quadrivalent was designed to demonstrate that its 
immunogenicit y and safet y were com parable to those previously established for FluMist since 
1) Fl uMist Quadrivalent differs from FluMist only  in the number of influenza v irus strains; 2) 
both Fl uMist and FluMist Quadrivalent are manufactured in an ident ical manner; 3) both 
FluMist and FluMist Quadrivalent are based on the same MDV strains; 4) the total viral 
content of FluMist Quadrivalent does not exceed the maximal calcu lated viral content of 
FluMist; and 5) inactive components of FluMist and FluMist Quadrivalent are ident ical. 
Because of these similarit ies, only select nonclinical pharmaco logic studies were conducted 
with FluMist Quadrivalent, with FluMist as comparator. Repeat -dose and reproductive and 
developmental toxico logy studies were repeated wit h FluMist Quadrivalent.
Primary pharmacodynamic studies in ferrets have been conducted to evaluate the replicat ion 
and immunogenicit y of live, attenuated FluMist strains. R esults of replicat ion, 
immunogenicit y, and challenge studi es in ferrets demonstrated that vaccinat ion with FluMist 
protected animals fo llowing challenge with wild- type virus; vaccine -induced immunit y in 
these animals substant ially decreased replicat ion of the wild -type vi rus in the l ungs as well as 
the upper airways. Studies with FluMist Quadrivalent demonstrated that it was equally 
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
12of 74 Template 16.2immunogenic, had similar replicat ion kinet ics, and conferred equally  efficient protecti on 
following challenge wit h wild -type viruses.
Toxicology  studi es performed wi th FluMist and/or FluMist Quadrivalent include 2 repeat -
dose toxi cology studi es in ferrets, 2 reproductive toxico logy studi es in rats and ferrets, and 
2ocular toxi cology studies (Drai ze tests) in a rabbit model to ev aluate the potenti al effects of 
FluMist if inadvertent ly sprayed into the ey e. 
A single -and repeat -dose toxico logy study  was conducted in ferrets to invest igate the 
potenti al adverse effects of FluMist given once or 3 times to ferrets over a 15 -week peri od. 
The regimen consisted of up to 3 human doses of FluMist administered intranasally at 
Weeks 0, 4, and 14. This dosing regimen is in co mpliance wit h Internat ional Council for 
Harm onisat ion (ICH) Guideline M3, which recommends a toxicit y study  durati on of 3months 
with a product dosing duration of up to 1 month. No clinical indicat ions of toxicity were 
manifest during the course of the study  from any of the parameters evaluated. No test 
materi al-related toxi city was i dentified in the majo r organs examined histopathologically, 
except for increased incidence o f acute, m ultifocal, suppurative inflammat ion of the nasal 
turbinates and lymph node hy perplasia in animals at i nterim necropsy . These findings were 
most likely due to inocul ation 3 days prior to necrops y and the ant igenic responses of the 
animals to the inoculum. Overall, in this study  and a similar repeat -dose study conducted with 
FluMist Quadrivalent in ferrets, the vaccine was well tolerated. 
Studi es wi th FluMist were conducted to evaluate reproducti ve and developmental toxico logy 
in 2 different animal models (rat and ferret). Results of the study  conducted wi th rats indicated 
that exposure to FluMist once prior to mating and once during pregnancy did not produce any  
maternal toxicit y or affect the re productive capacit y of the dam . These exposures did not 
produce embry o
-fetal toxicity in near -term fetuses or pups evaluated for 21 days postpartum . 
Results of a similar study  in which quadrivalent FluMist was administered 3 times prior to 
mating and again 3 times during gestation showed no safet y concerns.
The study  in ferrets invo lved intranasal administratio n of FluMist to pregnant ferrets at 
4different time points during gestation. No vaccine treatment -related effects were observed 
with respect to m aternal mortalit y, clinical  observati ons, or body  weight during gestation, nor 
were there any  treatm ent-related effects observed in fetal parameters or in maternal 
macroscopic pathology  that coul d be attributed to the intranasal inst illation of FluMist. 
The potenti al for ocul ar toxi city resul ting from the inadvertent instillat ion of FluMist into the 
eye was evaluated in 2 ocular toxicit y studi es in rabbits using a standard Draize test. Neither 
study  elici ted resul ts consistent wi th ocular toxicity .
The result s of the nonclinical studies performed with FluMist and FluMist Quadrivalent 
collect ively demo nstrate that the vaccine has a favorable safet y and tol erabilit y profile.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
13of 74 Template 16.21.4 Summary of Clinical Experience
In over 60 clinical studies, more than 120,000 subjects f rom 6 weeks to > 90 years of age have 
been administered MedImmune’s egg -produced vaccine, FluMist. These studies were 
designed to evaluate the safet y, efficacy, and immunogenicit y of the vaccine among various 
study  popul ations, including > 90,000 children and adol escents 6 weeks to 17 y ears of age and 
> 30,000 adults 18 to > 90 y ears of age. In these studies, FluMist was found to be generally  
safe and well tolerated. In healthy adults 18 through 64 y ears of age, Fl uMist reci pients 
reported higher rates of r unny nose (44%) and sore throat (26%) than placebo recipients (27% 
and 17%, respectively ), with a median event duration of 1 day  regardless of treatm ent 
received. Other symptoms, including cough, headache, chills, muscle aches, and 
tiredness/weakness occur red less often and at similar rates between the treatment groups. 
Low-grade fever (temperature > 100ºF) occurred at a similarly low rate for FluMist and 
placebo reci pients (1.3% and 1.5%, respectively).
The clinical development of FluMist Quadrivalent incl uded 2 pivotal , doubl e-blind studies 
conducted in the USA, one in children and ado lescents 2 to 17 years of age (MI -CP208; 2,312 
subjects) and one in adults 18 through 49 y ears of age (MI -CP185; 1,800 subjects), both of 
which demo nstrated that the immune r esponses generated by  FluMist Quadrivalent were 
noninferior to the immune responses generated by  FluMist and the safety  and tol erabilit y 
profiles of the 2 vaccines were similar in both populat ions. Result s of an addit ional study  (MI-
CP206; 1,800 subjects), conducted in adults using FluMist Quadrivalent delivered by a novel 
blow fill seal (BFS) delivery system, also demonstrated that the immune responses generated 
by FluMist Quadrivalent were noninferior to the immune responses generated by  FluMist 
delivered by Becton Di ckinso n (BD) Accuspray™, and provi ded support for the similar safety  
profile of FluMist Quadrivalent. Overall, a total of 3,783 subjects received at least 1 dose of 
FluMist Quadrivalent in the 3 studies, including 1,199 subjects who received F luMist 
Quadrivalent in the BFS device. A total of 1,386 FluMist Quadrivalent recipients were 2 years 
to less than 18 y ears of age and, of these, 1,041 subjects received 2 doses.
In addit ion to the clinical study experience, over 200,000 doses of FluMist ha ve been 
administered in 2 post -marketing studies, and more than  of FluMist have 
been distributed commercially worldwide fro m initial licensure in 2003. FluMist was init ially 
approved for use in healt hy individuals 5 to 49 y ears of age; ho wever, the age indicat ion was 
expanded to include children 24 to 59 months of age prior to the 2007 -2008 influenza season. 
For thi s study  populati on, there are no risks ant icipated other than those described in the 
package insert ( Appendix 3).
The 2017
-2018 Fl uMist Quadrivalent Package Insert ( Appendix 3) provi des the m ost current 
safet y data and product use informat ion.

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
14of 74 Template 16.21.5 Rationale for Conducting the Study
The Worl d Heal th Organizat ion (WHO) has made the fo llowing recommendation to vaccine 
manufacturers, effect ive 22Feb2018, regarding the influen za vaccine com position for the 
2018- 2019 influenza season:
A/Michigan/45/2015 -like virus H1N1pdm09
A/Singapore/INFIMH -
16-0019/2016 -like virus (H3N2)
B/Phuket/3073/2013 -like virus (Yamagata lineage; for quadrivalent formulat ions)
B/Colorado/06/2017 -like virus (Vi ctoria lineage)
Thus, in accordance wit h this change and these guidelines ( Centers for Disease Control and 
Prevent ion [CDC], 2016) , MedImmune has selected the fo llowing strains to be FluMist 
Quadrivalent components in the 2018- 2019 influenza season:
A/Slo venia/2903/2015 V8 (H1N1)
A/Singapore/INFIMH -
16-0019/2016 V2 (H3N2) 
B/Phuket/3073/2013 (Yamagata lineage)
B/Colorado/06/2017 (Victoria lineage)
B/Phuket/3073/2013 (Yamagata lineage) has been 1 of the strains contained in FluMist since 
the 2015 -2016 season, and A/Slovenia/2903/ 2015 (H1N1) was a new strain in the 2017 - 2018 
season. 
As a result, this study , conducted in healthy adults, will evaluate the safet y of a bivalent 
vaccine containing 2 new influenza virus reassortan ts A/Singapore/INFMH -16-0019/2016 and 
B/Colorado/06/2017 prior to the release of the quadrivalent vaccine (FluMist Quadrivalent) 
containing them.
1.6 Research Hypothesis
The hypothesis for this study  is that 2 new live attenuated influenza strains based on Ann
Arbor MDVs ( Maassab, 1968 ; Maassab et al , 1985 ) will have a safet y and tol erabili ty profile 
consistent with previously evaluated strains produced using this technology.
2 OBJECTIVE
2.1 Primary Objective
The obj ective o f this study  is to assess the safet y of a bivalent influenza virus vaccine of 
2new 6:2 influenza virus reassortants in healt hy adults prior to the release of the quadrivalent 
vaccine (FluMist Quadrivalent) containing them.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
15of 74 Template 16.22.2 Study Endpoints
2.2.1 Prim ary Endpoint
The primary  endpoint of this study  is fever (Days 1 through 8), defined as oral temperature 
≥101°F. 
2.2.2 Secondary Endpoints
1Solicited symptoms that occur within 7 days after vaccination (Days 1 -8)
2Adverse events (AEs) that occur wi thin 7 days after vaccinat ion (Day s 1-8)
3Solicited symptoms that occur within 14 days after vaccinat ion (Days 1 -15)
4AEs that occur within 14 days after vaccinat ion (Days 1 -15)
5Serious adverse events (SAEs) that occur within 28 day s after vaccinat ion (Days 1-29) 
6New onset chronic diseases (NOCDs) that occur wit hin 28 days after vaccinat ion (Days 
1-29) 
7SAEs that occur within 180 days after vaccinat ion (Day s 1
-181)
8NOCDs that occur within 180 days after vaccinat ion (Days 1 -181)
3 STUDY DESIGN
3.1 Description of t he Study
3.1.1 Overview ..........
This prospective, rando mized, double -blind, pl acebo -controlled release study  will enroll  
approximately  300 heal thy adults 18 through 49 y ears of age (not y et reached their 50th 
birthday ). Eligible subjects will be randomly assig ned in a 4:1 fashio n to receive a single dose 
of bivalent vaccine or placebo by  intranasal  spray . This study  will be conducted at 2 sites in 
the USA. Rando mizat ion will be stratified by  site.
Each subject will receive one dose of invest igational product on Day 1. Subj ects will be 
followed through 180 day s after recei pt of invest igational product.
A study  schemat ic is provided in Figure 1.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
16of 74 Template 16.2Figure 1 Study Flow Diagram
The endpo ints to be measured in this study  are described in Sect ion2.2.
3.1.2 Treatm ent Regimen
Subjects will be rando mly assigned in a 4:1 ratio to receive a single dose of either bi valent
vaccine (240 subjects) or placebo (60 subjects) by intranasal spray on Day 1.
3.2 Study Design and Dose Rationale
3.2.1 Dose Rationale
The influenza vaccine virus dose to be used i n this study , a single dose of 107.0±0.5fluorescent 
focus uni ts per strain, i s the same as the dose that will be used in the commercial FluMist 
Quadrivalent product.
3.2.2 Rationale for Study Population
Healthy adul ts 18 through 49 y ears of age represent the segment of the adult populat ion for 
whom FluMist Quadrivalent is indicated and, in contrast to children, are not a vulnerable 
popul ation. The study’s eligibilit y criteria are intended to prevent enrollment of individuals 
with medical  condi tions in who m FluMist Quadrivalent is not indicated, to minimize 
confounding circumstances that would impair the abilit y to interpret the study  resul ts, and to 
maximize the proportion of enro lled subjects complet ing the study.

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
17of 74 Template 16.23.2.3 Rationale for Endpoints
Fever has been chosen as a primary  endpoint, because i t is a commo n and object ive 
consequence o f infect ion with wild -type influenza. Fever occurring at a greater rate in the 
vaccine group than the placebo group would, therefore, suggest that new influenza vaccine 
virus strain smight not be sufficient ly attenuated. Regulatory authorit ies have accepted this 
measure of attenuation of new influenza vaccine virus strains over many years and have 
requi red thi s testing pri or to thei r authorizing release of the FluMist or FluMist Quadri valent 
vaccine containing any  new influenza strains each year.
Secondary  endpoints of the study  include other reported solicited symptoms and AEs that 
occur wi thin 7 days after vaccinat ion (Days 1 -8), and all so licited symptoms and AEs that 
occur wi thin 14 days after vaccinat ion (Days 1 -15). Addi tional secondary  endpoints include 
SAEs and NOCDs that occur within 28 days after vaccination (Days 1 -29) and wi thin 180 
days after vaccinat ion (Day s 1-181).
The reporti ng period of 14 day s (Days 1 through 15) for s olicited symptoms, including fever, 
and AEs is consistent with the incubat ion peri od of influenza.
4 MATERIALS AND METHOD S
4.1 Subjects
4.1.1 Number of Subjects
This study  will enroll approximately 300 healthy adults 18 through 49 y ears of age (not y et 
reached their 5 0th bi rthday). Eligible subjects will be randomly assigned in a 4:1 fashio n to 
receive a single dose of bivalent vaccine or placebo by  intranasal spray.
4.1.2 Inclusion Criteria
Subjects m ust m eet all of the fo llowing cri teria:
1Age 18 through 49 y ears at the tim e of screening (not yet reached their 50 thbirthday).
2Written inform ed consent and any  locally requi red authori zation (ie, Heal th Insurance 
Portabilit y and Accountabilit y Act [HIPAA] in the USA) obtained from the subject/legal 
representative prior to perfo rming any protocol -related procedures, including screening 
evaluat ions.
3Female subjects of childbearing potential who are sexually act ive wit h a nonsterilized 
male partner must use a highly effect ive method of contraception for 30 day s prior to the 
first dose of invest igational product and must agree to continue using such precaut ions for 
60days after the final dose of invest igational product; cessat ion of contraception after this 
point shoul d be discussed wit h a responsible physician. It is strongly recom mended for 
the male partner of a female subject to also use male condo m plus spermicide throughout 
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
18of 74 Template 16.2this peri od. Peri odic abst inence, the rhyt hm method, and the withdrawal method are not 
acceptable methods of contraception.
Females of childbearing potential are defined as those who are not surgically  sterile 
(ie, surgi cal sterilizati on includes bilateral  tubal  ligati on, bilateral  oophorectomy , or 
complete hysterectomy) or postmenopausal (defined as 12 months with no menses 
without an al ternat ive medical caus e).
A highly effect ive method of contraception is defined as one that results in a low 
failure rate (ie, less than 1% per y ear) when used consistent ly and correctly. 
Examples of acceptable methods of contraception are described in Table 1. 
4Nonsterilized male subjects who are sexually active with a female partner of childbearing 
potenti al must use a m ale condom  with spermicide from  Day  1 through Day  31,or at l east 
30 day s after recei pt of the final  dose of invest igational product. It is strongly 
recommended for the female partner of a male subject to also use a highly effect ive 
method of contraception throughout this period, as shown in Table 1. In addit ion, male 
subjects must refrain fro m sperm  donati on for 30 days after the final dose of 
investigat ional product as the only  dose of invest igational pr oduct occurs on Day  1.
Table 1 Highly Effective Methods of Contraception
Barrier Methods Hormonal Methods
• Copper T intrauterine device
• Levonorgestrel -releasing intrauterine system) 
(eg, Mirena®) a• Implants
• Hormone shot or injection 
• Combined pill
• Minipill
• Patch
aThis is also considered a hormonal method.
5Healthy by  medical  history  and physical examinat ion
6Female subjects of childbearing potential must also have a negat ive urine or blood 
pregnancy test at screening and, if screening and Day 1 do not occur on the same day, on 
the day  of vaccinat ion prior to randomizat ion
7Subject available by telephone
8Abilit y to understand and comply with the requirements of the protocol, as judged by  the 
investigator
9Abilit y to complete fo llow-up peri od of  180 day s after dosing as required by  the protocol
4.1.3 Exclusion Criteria
Any of the fo llowing woul d exclude the subject from participat ion in the study :
1Any condit ion that, in the opinio n of the invest igator, would interfere with evaluat ion of 
the invest igational product or interpretation of subject safet y or study resul ts
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
19of 74 Template 16.22Concurrent enrollment in another clinical study  up to 180 days after receipt of 
investigat ional product (Day  181) 
3Employees of the clinical study  site or a ny other individuals invo lved with the conduct of 
the study , or immediate family members of such individuals
4History  of hypersensi tivity to any  com ponent of the vaccine, including egg or egg 
proteins or serious, life threatening, or severe reactio ns to pre vious influenza vaccinat ions
5History  of hypersensi tivity to gentamicin, gelat in, or arginine
6Any condit ion for which the inact ivated influenza vaccine is indicated, including chronic 
disorders of the pulmo nary or cardi ovascular systems (eg, asthma), chroni c metabo lic 
diseases (eg, di abetes mellitus), renal dysfunct ion, or hemoglobinopathies that required 
regul ar medical fo llow-up or hospi talizat ion during the preceding year
Note: A history of asthma that requires regular medical follow -up or hospitalization during 
the preceding 2 years is exclusionary. Investigator judgment is required to determine w hether 
or not a subject has a history of asthma; how ever, for adult subjects, a remote history of 
wheezing or a remote diagnosis of asthma that the investigator does not consider to be 
relevant to current health does not need to be considered to be a history of asthma.  For 
example, childhood asthma that has not required treatment in adulthood is not necessarily 
exclusionary.
7Acute febrile (> 100.0°F oral or equi valent) and/or clinically  significant respi ratory  illness 
(eg, cough or sore throat) within 14 days prior to rando mizat ion
8Any known immunosuppressive condit ion or immune deficiency  disease, including 
human immunodeficiency virus infect ion, or ongoing immu nosuppressive therapy
9History  of Guillain -Barre syndrom e
10A househo ld contact who is severely immunocompromised (eg, hematopoietic stem cell 
transpl ant reci pient, during those periods in which the immunocompro mised individual 
requi res care in a protective e nvironment); addit ionally , subject shoul d avoi d close 
contact wi th severely  immunocom promised individuals for at least 21 days after receipt 
of investigational product
11Receipt of any  investi gational agent wi thin 30 days prior to randomizat ion, or expected 
recei pt through 30 days after the dose of investigatio nal product (use of licensed agents 
for indicat ions not listed in the Package Insert is permitted) 
12Receipt of any  non-study  vaccine wi thin 30 days pri or to randomizat ion, or expected 
recei pt through 30 days after receipt of invest igational product
13Expected receipt of ant ipyretic or analgesic medication on a daily or every other day basis 
from randomization through 14 day s after recei pt of investigational product
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
20of 74 Template 16.2Note: A daily dose of up to 81 mg of asp irin for prophylactic use is not considered a 
contraindication to enrollment.
14Administrati on of  intranasal medications within 14 day s prior to randomization, or 
expected receipt through 14 days after administration of invest igational product
15Receipt of inf luenza ant iviral therapy or influenza ant iviral agents wi thin 48 hours pri or to 
investigat ional product administration or expected receipt of influenza ant iviral therapy or 
influenza antiviral agents through 14 days after receipt of invest igational product
16Known or suspected mitochondrial encephalo myopathy
17Nursing mother
4.1.4 Subject Enrollment and Randomization
Study  parti cipat ion begins (ie, a subject is “enro lled”) once written informed consent is 
obtained. Once informed consent is obtained, a subject ident ificat ion (SID) number will be 
assigned by  a central  system  (eg, an interactive web response system, IWRS) , and the 
screening evaluat ions m ay begin to assess study  eligibilit y (inclusio n/exclusio n) cri teria. The 
SID number will be used to ident ify the subject during the screening process and throughout 
study  participati on, if applicable. 
Subjects will be rand omized at a 4:1 ratio to receive either a single dose of bivalent vaccine or 
placebo by  intranasal  spray . Randomizat ion will be stratified by  site.
A master log of all consented subjects will be maintained at the site and will document all 
screening failur es (ie, subjects who are consented but do not meet study  eligibilit y criteria 
and/or are not randomized), including the reason(s) for screening failure.
Subjects who fail to meet the inclusio n/exclusio n criteria (ie, screening failures) should not be 
rando mized (if applicable) or receive invest igational product.
4.1.5 Withdrawal from  the Study
Subjects are at any  time free to wi thdraw from  the study  (invest igational product and 
assessments), without prejudice to further treatment (withdrawal o f consent). Such sub jects 
will always be asked about the reason(s) and the presence of any AEs. If possible, they will be 
seen and assessed by an investigator. Adverse events will be fo llowed up and any worksheets 
will be co llected. If a subject withdraws fro m further partici pation in the study , then no further 
study  visits or data collect ion shoul d take pl ace.
4.1.6 Replace ment of Subjects
Subjects will not be replaced.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
21of 74 Template 16.24.1.7 Withdrawal of Informed Consent for Data
Study  data are protected by  the use of an SID number, which is a number s pecific to the 
subject. The invest igator is in control of the information that is needed to connect a study 
sample to a subject. A subject’s consent to the use of data does not have a specific expirat ion 
date, but the subject may wit hdraw consent at any  time by notifying the invest igator. If 
consent is withdrawn, any data collected prior to that time may st ill be given to and used by  
the sponsor but no new data will be co llected unless specifically required to monitor safety o f 
the subject.
4.2 Schedule of Stud y Procedures
A schedule o f study  procedures i s provi ded in Table 2, followed by  a descri ption of each visit. 
A descript ion of study  procedures i s prov ided in Section 4.2.1 .
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
22of 74 Template 16.2Table 2 Schedule of Study Procedures
Study Period Screening Treatment Follow -up
Visit Visit 1 Visit 2Unscheduled 
Visit Telephone Contact
Procedure/Study Day Days -14 to 1 Day 1 Days 2 to 15Days 2 
to 15Day 31 
(+7)Day 
61(+7) Day 
91(+7) Day 
121 
(+7) Day 
151 
(+7) Day 
181 
(+14) 
Written informed consent/ assignment 
of SID numberX
Verify  eligibility  criteria X X
Medical history & current medication 
useX X
Physical examination, height, weight, 
& temperatureX XaX
Pregnancy test X Xa
Collect SAEs X X X X X X X X X X
Randomization X
Collect concomitant medications X X X X
Collect AEs X X X X
Collect solicited symptoms X X X
Collect NOCDs X X X X X X X X X
Investigational Product 
AdministrationX
AE = adverse event; NOCD = new onset chronic disease; SAE = serious adverse event; SID = subject identification number
aIf screening and dosing occur at the same visit, only one evaluation is required (female subjects only, unless exempt from pregnancy testing) . 
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
23of 74 Template 16.24.2.1 Screening Visit (Visit 1)
All screening procedures must be performed within 14 days before or on the same day  as 
investigat ional product administration (Day  -14 to Day  1). The screening evaluat ions may be 
carried out over m ore than one visit. Written informed consent and any  locally requi red 
privacy  act docum ent authori zation m ust be obtained prior to performing any protocol -specific 
procedures, including screening evaluat ions.
1Obtain written informed consent and appropriate privacy act document authorizat ion 
2Assign an SID number
3Verify eligibilit y criteria
4Obtain screening medical history
5Record current medicat ion use
6Perform  screening physical examinat ion, including temperature, height, and weight
7Collect urine sample for pregnancy test (female subjects only, unless exempt from 
pregnancy testing); if screening and dosing o ccur at the same visit, only one test is 
requi red
8Assess for AEs, SAEs, and concomitant medicat ion use
4.2.2 Treatm ent Period (Visit 2)
Day 1: Administration of Investigational Product
1Verify eligibilit y criteria
2Update screening medical history , current medication use (any new findings since 
screening), and physical examinat ion (including height, weight, and temperature)
3Collect urine sample for pregnancy test (female subjects only, unless exempt from 
pregnancy testing); if screening and dosing occur at t he same visit, only one test is 
requi red; result must be negat ive for randomization and dosing to occur 
4Assess for AEs and SAEs
5Randomize in IWRS to assign invest igational product spray er number
6Administer invest igational product 
7Observe subject for a mi nimum of 15 minutes. Provide safet y assessment worksheets, 
thermometer, and instructions for complet ing the worksheets (see Section 5.5.2 ). Ensure 
that the subject understands how to take his/her temperature. Day  1 tem perature i s 
recorded by  the subject in the evening of Day  1 (day  of invest igational product 
administration). The safet y assessment worksheets will be used for the collect ion of 
solicite d symptom s, AEs, and concomitant medication use, and will be completed by  the 
subject to serve as a memory aid for future data collect ion by study  staff during tel ephone 
contacts.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
24of 74 Template 16.28Record solicited symptoms, AEs, and concomitant medicat ion use
9Inquire about SAEs and NOCDs
4.2.3 Follow- up Period (Unscheduled Visit and Telephone Contacts)
4.2.3.1 Unscheduled Visit, Days 2 to 15 for Significant Febrile Illness
1Perform  medical  evaluat ion 
2Record solicited symptoms, AEs, and concomitant medicat ion use 
3Inquire about SAEs and N OCDs
4.2.3.2 Telephone Contact, Days 2 to 15
Telephone contact every day or every other day to Day 15
1Record solicited symptoms, AEs, and concomitant medicat ion use
2Inquire about SAEs and NOCDs
4.2.3.3 Telephone Contact, Days 31, 61, 91, 121, 151 (+ 7 days)
One telephon e contact each between Days 31 and 38, 61 and 68, 91 and 98, 121 and 128, 
and 151 and 158
1Inquire about SAEs and NOCDs
4.2.3.4 Telephone Contact, Day 181 (+ 14 days): Last Follow -up Contact and Study 
Termination
One telephone contact between Days 181 and 195
1Inquire about SAEs and NOCDs through 180 day s post dosing
4.3 Description of Study Procedures
4.3.1 Medical History and Physical Examination, Height, Weight, and 
Temperature
Medical history  and current m edicat ion use will be collected. A basic physical examinat ion of 
the head, neck, chest, heart, abdomen, and extremities will be performed, to include collect ion 
of height, weight, and temperature (oral thermo meter).
4.3.2 Clinical Laboratory Tests
The only clinical laboratory  tests perform ed in this study  will be urine pre gnancy  tests.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
25of 74 Template 16.2Pregnancy Test (females of childbearing potential only)
• Urine human chorionic gonadotropin (hCG; at screening and day of randomization if screening and 
randomization/dosing do not occur on the same day ).
4.4 Investigational Products
4.4.1 Identity of Investigational Products
MedImmune will provide the invest igators with investigational product ( Table3) using 
designated distribut ion centers. 
Table3 Identification of Investigational Products
Investigational Product ManufacturerConcentration and Formulation as 
Supplied
Bivalent influenza vaccine MedImmune107.0 ± 0.5FFU of each of 2 ca, att, ts, 6:2 
reassortant influenza strains per 0.5 mL  
 in the BD Accuspray device:
A/Singapore/INFIMH -16-0019/2016 V2
B/Colorado/06/2017
Placebo MedImmune 0.5 mL of  in the BD Accuspray 
device
att= attenuated; BD = Becton Dickinson; ca= cold adapted; ; FFU = fluorescent focus unit;  
ts= temperature sensitive
Invest igational product will be packaged and stored at -30°C and shipped to the study site 
upon request of the sponsor or designee. The distributor will sh ip the invest igational product 
directly to the clinical study site by express courier. Receiving departments should be notified 
that rapid handling of the shipment is required. Upon receipt at each study  site, frozen 
investigat ional product should be immed iately transferred to a -20°C (or -4°F) freezer 
(variations up to ± 5°C are acceptable) in a secure locat ion with limited access. 
Invest igational product will be supplied to the site in devices wit h ident ical appearances in 
coded ki ts. Each ki t has a uni que number that i s printed on all labels wit hin the kit (ie, the 
outer carton label and the label o f each device within the carton). Labels will be prepared in 
accordance with Good Manufacturing Practice (GMP) and local regulatory  guidelines. 
Invest igational product shoul d not be rem oved f rom storage until  the day of dosing (Day  1); 
investigat ional product may be stored at room temperature during the day  of dosing. Any 
broken or damaged sprayer must be ident ified as damaged and the sprayer number recorded 
on the investigational product accountabilit y record. Damaged sprayers can be stored at room 
temperature until accountabilit y is co mpleted.

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
26of 74 Template 16.24.4.1.1 Investigational Product Inspection
At room  temperature, invest igational product is a colorless to pale yellow liquid, and cl ear to 
slight ly cloudy . Som e proteinaceous parti cles may  be present but they  do not affect the use of 
the product. If there are any  defects noted with the investigat ional product, the investigator 
and site monitor should be notified immediately.  Re fer to the Product Complaint sect ion for 
further instructions.
4.4.1.2 Treatment Administration
The first day  of dosing is considered Day 1.
Invest igational product should be brought to room temperature by  holding the sprayer in 
the palm o f the hand and supporting the plunger rod with the thumb (see Appendix 3). 
The invest igational product should be administered immediately thereafter.
A single administration co mprises intranasal delivery  of approximately 0.5 m L total  
volume (0.25 mL into each nostril). Each sprayer has a divider that allo ws delivery of 
approximately  half the contents of the spray er into one nostril. Remo val o f the divider 
allows delivery  of the rem aining vo lume into the other nostril.
The individual administering the invest igational product should depress the plunger rod a s 
rapidly as possible to generate a fine mist. Half of the contents of each sprayer will be 
spray ed as a fine mist into each nostril while the subject is in an upright posit ion.
After administration, used study  sprayers must be placed immediately  after use into 
locked containers or sealed bags.
4.4.1.3 Monitoring of Dose Administration
After vaccination, all subjects will be observed for a minimum of 15 minutes by the study 
staff. Emergency management supplies (eg, AMBU bag, adrenaline [epinephrine], 
antihistamine
) will be made available for the init ial treatment of an allergic react ion if needed. 
Local  reacti ons or sy stemic events m ust be recorded.
As wi th any vaccine, allergic reactions to dose administration are possible. Therefore, 
appropriate drugs and medical equipment to treat acute anaphylact ic react ions must be 
immediately  available, and study  personnel must be trained to recognize and treat 
anaphylaxis.
4.4.1.4 Reporting Product Complaints
Any defects with the invest igational product must be reported immediately to the MedImmune 
Product Complaint Department by  the si te wi th further notificat ion to the site monitor. All 
defects will be communicated to MedImmune and investigated further with the Product 
Com plaint Department. During the invest igation of the product co mplaint, all invest igational 
product must be stored at labeled condit ions unless otherwise instructed.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
27of 74 Template 16.2MedImmune contact informat ion for reporting product complaints:
Email: productcom plaints@medimmune.com
4.4.2 Additional Study Medications
No other study  medicat ions are specified for use in this clinical protocol.
4.4.3 Labeling……………….  
Labels for the investigational product will be prepared in accordance wit h GMP and local 
regul atory  guidelines. The label will fulfill GMP Annex 13 requirements for labeling. Label 
text will be translated into local languages, as required.
4.4.4 Storage ………………….
Invest igational product must be stored in the original outer package and must not be thawed. 
The m anufacturer’s instructions for shipment and storage will be followed at all times. It is the 
responsibilit y of the invest igator to maintain daily tem perature l ogs f or the freezer, at a 
minimum, daily Monday  through Fri day. The investi gator will be provi ded wi th temperature 
monitors that record minimum/maximum temperatures, unless temperature monitors are 
already in place.
4.4.5 Treatm ent Compliance
Invest igational product i s administered by study  site personnel, who will mo nitor com pliance.
4.4.6 Accountability
The invest igator’s or site’s designated invest igational product manager is required to maintain 
accurate investigat ional product accoun tabilit y records. Upo n complet ion of the study , copi es 
of investigational product accountabilit y records will be returned to MedImmune. All unused 
investigat ional product will be returned to a MedImmune -authori zed depot or di sposed of 
upon authorizat ion by MedImmune.

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
28of 74 Template 16.24.5 Treatment Assignment and Blinding
4.5.1 Methods for Assigning Treatment Groups
An IWRS will be used for randomizat ion to a treatment group and assignment of blinded 
investigat ional product sprayer numbers. A subject is considered rando mized into the study  
when the inves tigator notifies the IWRS that the subject meets eligibilit y criteria and the 
IWRS provides the assignment of blinded invest igational product spray er numbers to the 
subject.
Subjects will be randomized at a 4:1 ratio to receive either bivalent influenza va ccine or 
placebo. The randomization will be stratified by sit e.
Invest igational product (bivalent influenza vaccine or placebo) must be administered the same 
day the invest igational product is assigned. If there is a delay in the administration of 
investigat ional product such that it will not be administered within the specified timeframe, 
the study  monitor m ust be notified immediately.
4.5.2 Methods for Ensuring Blinding
This is a double -blind study  in which bivalent influenza vaccine and placebo are ident ically
labeled and indist inguishable in appearance. As such, neit her the subject/legal representative 
nor any  of the invest igator or sponsor staff who are invo lved in the treatment or clinical 
evaluat ion of the subjects will be aware of the treatment received (I CHE9; see Section 4.5.3.2
for unblinding related to interim planned analysis). In the event that treatment allocat ion for a 
subject becomes known to the investigator or other study  staff invo lved in the management of 
study  subjects, the sponsor must be notified immediately . 
4.5.3 Methods for Unblinding 
4.5.3.1 Unblinding in the Event of a Medical Emergency 
In the event of a medical emergency, the invest igator m ay unblind an individual subject’s 
investigat ional product allocat ion. Prior to unblinding the invest igational product allocat ion 
for an individual subject, the invest igator must first attempt to contact the medical mo nitor to 
discuss the medical emergency and the reason for want ing to unblind. Instructions for 
unblinding an individual subject’s invest igational product allocation are contained in the 
IWRS manual. In general, unblinding should only occur if management of the medical 
emergency woul d be differ ent based on the subject having received invest igational product. In 
the majorit y of cases, the m anagement of a medical emergency  woul d be the same whether or 
not invest igational product was received by the subject. If this was the case, the 
investigat ional product allocat ion shoul d not be unblinded. 
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
29of 74 Template 16.2MedImmune retains the right to unblind the treatment allocat ion for SAEs that are unexpected 
and are suspected to be causally related to an investigat ional product and that potentially 
requi re expedited report ing to regulatory authorities. 
4.5.3.2 Unblinding for Interim Analysis 
An interim analysis is planned for this study  as described in Sect ion4.7.4 . To ens ure the 
blinding of each subject’s treatment assignment throughout the study , the Day  15 unblinded 
analyses will be performed by defined MedImmune personnel, including the medical mo nitor, 
the clinical program manager, Patient Safet y staff team  members, Re gulatory  (Clinical ) staff 
team  members, a Medical Writ ing staff team member, a Biostatistics staff team member, 
Clinical Statist ical Analysis System Programming staff team members, and Data Management 
(including data management vendor’s non -MedImmune perso nnel) staff team members. Study  
site personnel and contract research organizat ion personnel direct ly associated with the 
conduct of this study  and the subjects will remain blinded to the treatment assignment for 
individual subjects unt il the co mpletion o f the study. 
4.6 Restrictions During the Study and Concomitant Treatment(s)
The Investigator must be informed as soon as possible about any  medicat ion taken from the 
time of screening until the end o f the clinical phase of the study  (final study  visit). Any 
concomitant medicat ion(s), including herbal preparations, taken during the study  will be 
recorded in the electronic case report form (eCRF).
4.6.1 Perm itted Concomitant Medications
Invest igators may prescribe concomitant medicat ions or treatments deemed necessary t o 
provi de adequate supportive care except for those medicat ions identified as “excluded” as 
listed in Section 4.6.2 . Specifically, subjects should receive full supportive care during the 
study , including transfusions of blood and blood products, and treatment with ant ibiotics, ant i-
emetics, ant i-diarrheals, and analgesics, and other care as deemed appropriate, and in 
accordance with their inst itutional guidelines.
4.6.2 Prohibited Concomitant Medications
Other than the medicat ions described above, use of concomitant medicat ions including over -
the-counter medicat ions, herbal supplements, vitamins, etc, fro m Day 1-15 is discouraged. 
Subjects m ust be instructe d not to take any medications, including over -the-counter products, 
without fi rst consul ting wi th the investi gator.
Use of antipyret ic or analgesic medications for all symptoms other than temperatures ≥101°F 
oral (or equivalent) is discouraged from Day 1-15. All medications taken during the 14- day 
post vaccinat ion follow
-up peri od, the indicat ions, the start and stop dates of the medicat ions, 
and the route of administration will be recorded from the time of informed consent through 
Day 15.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
30of 74 Template 16.2The fo llowing medications are exclusio nary. The sponsor must be notified if a subject 
receives any o f these during the study .
1Any vaccine or invest igational agent fro m 30 day s prior to randomizat ion through 30 days 
post invest igational product administration
2Any intrana sal medicat ion from 14 days prior to through 14 days post invest igational 
product administration
3Receipt of influenza ant iviral therapy or antiviral agents within 48 hours prior to 
investigat ional product administration or expected receipt of influenza ant iviral therapy or 
antiviral agents through 14 day s after recei pt of investi gational product
4.7 Statistical Evaluation
4.7.1 General Considerations
Data will be provided in data list ings sorted by  treatm ent group and subject ident ificat ion 
number. Tabular summaries will be presented by  treatm ent group. Categori cal data will  be 
summarized by  the number and percentage of subjects in each category . Continuous variables 
will be summarized by  descriptive stati stics, including mean, standard deviat ion, median, 
minimum, an d maximum . Confidence intervals (CIs) will be two -sided, unless otherwise 
stated.
The intent -to-treat (ITT) populat ion is defined as all subjects that are rando mized and treated 
with invest igational product. All analyses will be performed on the ITT popula tion unless 
otherwi se specified. Missing will be treated as missing and no data will be imputed. 
4.7.2 Sample Size and Power Calculations
It is expected that almost all subjects will provide informat ion on safety  and tol erabilit y. 
Table 4summarizes the solicited event rates fo llowing FluMist and placebo vaccination in 
healt hy adults 18 through 64 y ears of age in Study  AV009.
Table 4 Summary of Solicited Events (Days 0 Through 7) in Study AV009
Number of Subjects FluMist aPlacebo aDifference in 
Proportions 95% CI b
Randomized 3,041 1,520 -- --
Who returned diary cards 2,985 1,490 -- --
Who experienced solicited 
eventsn (%) n (%) -- --
Fever
Oral temperature > 100.0 F 40 (1.34) 20 (1.34) -0.00 (-0.01, 0.01)
Oral temperature 101.0F 17 (0.57) 9 (0.60) -0.00 (-0.01, 0.00)
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
31of 74 Template 16.2Table 4 Summary of Solicited Events (Days 0 Through 7) in Study AV009
Number of Subjects FluMist aPlacebo aDifference in 
Proportions 95% CI b
Oral temperature > 102.0 F 2 (0.07) 2 (0.13) -0.00 (-0.01, 0.00)
Oral temperature > 103.0 F 0 0 0.00 (-0.00, 0.00)
Runny nose 1,323 (44.32) 397 (26.64) 0.18 ( 0.15, 0.21)
Sore throat 793 (26.57) 243 (16.31) 0.10 ( 0.08, 0.13)
Cough 407 (13.64) 152 (10.20) 0.03 ( 0.01, 0.06)
Headache 1,172 (39.26) 555 (37.25) 0.02 (-0.01, 0.05)
Muscle aches 481 (16.11) 216 (14.50) 0.02 (-0.00, 0.04)
Chills 247 (8.28) 91 (6.11) 0.02 ( 0.00, 0.04)
Tired/weak 733 (24.56) 306 (20.54) 0.04 ( 0.01, 0.07)
Any solicited event 2,117 (70.92) 919 (61.68) 0.09 ( 0.06, 0.12)
CI = confidence interval
aSubjects counted if they experienced an event at least once within 7 days following vaccination.
bConfidence intervals for the difference in proportions are based on an exact method.
Power to show a similar fever rate with 300 evaluable subjects (240 bivalent vaccine and 
60placebo recipients) for varying true fever rates ranging fro m 0.5% to 2.0% in placebo 
recipients i s presented in Table 5. Accordingly, the currently proposed study  will provide at 
least 98% power to rule out a rate increase of 5 percentage points assuming the true difference 
between the treatment groups is zero and the true fever rate is ≤ 1%. Power i s lower if the true 
difference is different fro m zero. For example, if the true fever rates are 2% and 1% in vaccine 
and placebo recipients, respectively, the power will be 77%.
Table 5 Power to Show Similar Fever Rates for N = 300 Subjects
True Fever Rate
Exact Power aExact Type I Error Rate Vaccine Placebo
0.5% 0.5% 99.9% 2.2%
1.0% 1.0% 98.0% 2.3%
1.5% 1.5% 92.6% 2.3%
2.0% 2.0% 85.0% 2.3%
2.0% 1.0% 77.0% 2.3%
3.0% 1.0% 43.9% 2.3%
Note: Similar fever rates mean the ability to rule out a 5 percentage point increase in vaccine recipients. Total 
N includes 240 vaccine recipients and 60 placebo recipients.
aPower was computed using the method proposed by Chan and Zhang, 1999 .
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
32of 74 Template 16.2Power to show similar event rates for other solicited symptoms with 300 evaluable subjects 
(240 bivalent vaccine and 60 placebo recipients) for rates ranging from 6% to 37% in placebo 
recipients i s presented in Table 6. Accordingly, the currently proposed study  provi des at l east 
87% power to rule out a 20 percentage point increase, assuming the true difference between 
the 2 treatment groups is zero. Power is lower if the true difference is greater than zero.
Table 6 Power For Secondary Endpoints
Solicited EventsTrue Event RatesRate Increase to be 
Ruled Out (PPT) PoweraVaccine Placebo
Runny nose 27% 27% 20 94%
44% 27% 20 8%
44% 27% 36 90%
Sore throat 16% 16% 15 92%
27% 16% 15 13%
27% 16% 27 91%
Cough 10% 10% 15 99%
14% 10% 15 82%
14% 10% 17 93%
Headache 37% 37% 20 87%
Muscle aches 15% 15% 15 93%
Chills 6% 6% 10 95%
Tired/weak 21% 21% 20 98%
25% 21% 20 86%
25% 21% 21 90%
PPT = percentage point
Note: Total number includes 240 bivalent vaccine recipients and 60 placebo recipients.
aPower was computed using the method proposed by (Chan, 1998 ) and Proc -Stat (Version 6.2) software.
4.7.3 Endpoints............................
4.7.3.1 Primary Endpoint
The primary  endpoint of this study  is fever (Days 1 through 8), defined as oral temperature 
≥101°F. Comparison of the rate of fever between the 2 treatm ent groups will be based on the 
upper limit of the two- sided 95% exact CIs for the rate increase (bivalent vaccine minus 
placebo) evaluated against the pre -specified equivalence criterion of 5 percentage points.
This corresponds to the null hypothesi s of:
H0:  Rate difference ≥ 5 percentage points.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
33of 74 Template 16.2The al ternat ive hypothesis is:
HA:  Rate difference < 5 percentage points.
A two -sided 95% CI will be constructed using the exact method based on the score statistic 
proposed by  (Chan and Zhang, 1999 ). This m ethod com putes the l ower and upper confidence 
limits by inverting 2 separate one -sided tests of half the nominal Type I error rate. Its test 
statist ic is based on the score statist ic that is co mputed as the observed d ifference of the 
2binomial event rates minus the hypothesized value of the rate difference (observed rate 
difference) divided by the standard error of this difference under the alternative hypothesis. 
This test assures that the Ty pe I error does not excee d the pre -specified level. Due to 
discreteness when the sample size is relat ively small co mpared to the expected event rate, the 
associ ated Ty pe I error rate coul d be qui te conservative, that i s, sm aller than the pre -specified 
level.
4.7.3.2 Secondary Endpoints
Secondary  endpoints of the study  include other reported solicited symptoms and AEs that 
occur wi thin 7 days after vaccinat ion (Days 1 -8), and all so licited symptoms and AEs that 
occur wi thin 14 days after vaccinat ion (Days 1 -15). Addi tional secondary  endpoin ts include 
SAEs and NOCDs that occur within 28 days after vaccination (Days 1 -29) and wi thin 
180days after vaccinat ion (Days 1 through 181).
Fever will be summarized according to the fo llowing threshol ds:
Oral > 100°F
Oral ≥ 101°F
Oral > 102°F
Oral > 103° F
A secondary  analysis co mparing rates of other solicited symptoms (Days 1 -8) between the 
2treatm ent groups will be performed. Exact two -sided 95% CIs ( Chan and Zhang, 1999 ) on 
the rate difference (bivalent vaccine minu s placebo) will  be constructed. There are no pre -
specified equivalence criteria for the secondary analyses.
The number of days of so licited symptoms and the proportion of subjects experiencing each 
event by  study  day will be presented wi thout formal  statistical com parison. The distribut ion of 
the number of days with each individual event will also be summarized without formal 
statist ical comparison. The proporti on of  subjects using ant ipyretic and analgesic agents 
within 7 days after vaccination (Days 1- 8) and 14 days after vaccinat ion (Day s 1 -15) will  be 
summarized by  treatm ent group.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
34of 74 Template 16.24.7.4 Interim Analysis
A safet y analysis will be conducted after all subjects have been fo llowed through Day  15 and 
all data through at least Day  8 are l ocked. The analysis fo r Days 1 through 15 will include the 
primary  endpoint of this study  (fever for Day s 1-8, defined as oral temperature ≥101°F), as 
well as analysis o f safet y data (solicited symptoms and AEs), and ant ipyretics and analgesic 
use reported within 7 days and wi thin 14 days after dosing. To ensure the blinding of each 
subject’s treatment assignment throughout the study, the Day  15 unblinded analyses will be 
perform ed by  defined MedImmune personnel (see Section 4.5.3.2 ). Subsequent ly the 
unblinded results will be reviewed by the project statist ician, medical mo nitor, therapeutic 
area vice president, and the Head of Clinical Bio statistics and Data Management prior to 
approving the release of the unblinded study  resul ts to the proj ect team . Since the results of 
the interim analysis for the primary  endpoint will be final, the treatment codes will be sent to 
Patient Safet y within 1 business day  of the release of the study  resul ts to update the safet y 
databases. Study  site pe rsonnel  and contract research organizat ion personnel direct ly 
associ ated wi th the conduct of thi s study  and the subjects will remain blinded to the treatment 
assignment for individual subjects unt il the co mpletion of  the study . 
The results of the interim analysis will be reported to regulatory  authori ties in order to receive 
authori zation for release of the commercial product including the tested new vaccine virus 
strains.
After the study  is com plete and the database is locked, all data through 180 days af ter dosing 
will be summarized by  treatm ent group using the safet y popul ation.
5 ASSESSMENT OF SAFETY
5.1 Definition of Adverse Events
The ICH Guideline for Good Clinical Practice E6(R1) defines an AE as:
Any untoward medical occurrence in a patient or clinical i nvest igation subject 
administered a pharmaceutical product and which does not necessarily  have a causal  
relationship with this treatment. An AE can therefore be any unfavorable and unintended 
sign (incl uding an abnorm al laboratory  finding), symptom, or dis ease tem porally 
associ ated wi th the use of a m edicinal product, whether or not considered related to the 
medicinal product.
An AE includes but is not limited to any  clinically  significant worsening of a subject’s pre -
exist ing condit ion. An abnormal laborat ory finding (including electrocardiogram finding) that 
requi res medical intervent ion by the invest igator, or a finding judged by the invest igator as 
medically significant should be reported as an AE. If clinical sequelae are associated with a 
laboratory  abnorm ality, the di agnosis or m edical condit ion should be reported (eg, renal 
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
35of 74 Template 16.2failure, hematuria) not the laboratory  abnorm ality (eg, el evated creatinine, urine red blood cell 
increased). Abnormal laboratory  values that are not, in the invest igator's opinio n, medically  
significant and do not require intervent ion shoul d not be reported as AEs.
Adverse events may be treatment emergent (ie, occurring after init ial receipt of invest igational 
product) or nontreatment emergent. A nontreatment- emergent AE is any new sign or 
symptom , disease, or other untoward medical event that begins after written informed consent 
has been obtained but before the subject has received invest igational product. 
Elect ive treatment or surgery or preplanned treatment or surgery  (that was scheduled prior to 
the subject being enro lled into the study ) for a docum ented pre -existing condit ion that di d not 
worsen from baseline is not considered an AE (serious or nonserious). An untoward medical 
event occurring during the prescheduled elect ive p rocedure or routinely scheduled treatment 
shoul d be recorded as an AE or SAE.
5.2 Definition of Serious Adverse Events
An SAE is any  AE that:
Results in death
Is immediately life -threatening
Requi res inpat ient hospi talizat ion or prolongat ion of exist ing hospi talizati on 
Results in persistent or significant disabilit y/incapacit y 
Is a congenital ano maly/birth defect in o ffspring of the subject
Is an important medical event that may jeopardize the subject or may require medical 
intervent ion to prevent one of the outcom es listed above
Medical or scient ific judgment should be exercised in deciding whether expedited 
reporting is appropriate in this situat ion. Examples of medically important events are 
intensive treatm ent in an emergency  room  or at home for allergic bronchospasm, blood 
dyscrasias, or convulsio ns that do not result in hospitalizat ions; or development of drug 
dependency  or drug abuse.
5.3 Definition of Solicited Symptoms
Solicited symptoms are events that are considered likely to occur post dosing. For this study , 
solicited symptoms include:
Fever (> 100°F [37.8oC] oral )
Runny nose
Sore throat
Cough
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
36of 74 Template 16.2Vomit ing
Muscle aches
Chills
Decreased act ivity (tiredness)
Headache
5.4 Definition of New Onset Chronic Diseases
An NOCD is a newly diagnosed medical condit ion that i s of a chronic, ongoi ng nature and is 
assessed by  the invest igator as medically significant. Examples of NOCDs include but are not 
limited to di abetes, asthm a, autoimmune disease (eg, lupus, rheumatoid a rthritis), and 
neuro logical disease (eg, epilepsy , auti sm). Events that would not be considered NOCDs are 
mild eczema, diagnosis of a congenital ano maly present at study  entry , or acute illness (eg, 
otitis media, bronchit is). An NOCD should also be reporte d as an SAE if it meets the 
definit ion in Sect ion 5.2. If an NOCD occurs within 14 days post dosing, the event should also 
be reported as an AE (Se ction 5.1).
5.5 Recording of Adverse Events
Adverse events will be recorded on the eCRF using a recognized medical term or diagnosis 
that accurately re flects the event. Adverse events will be assessed by the invest igator for 
severit y, relationship to the invest igational product, possible etio logies, and whether the event 
meets cri teria of an SAE and therefore requires immediate notificat ion to MedImmune Patient 
Safety. See Section 5.2for the definit ion of SAEs and Appendix 2for guidelines for 
assessment of severit y and rel ationship. If an AE evo lves into a condit ion that m eets the 
regul atory  defini tion of  “seri ous,” i t will be reported on the SAE Report Form.
5.5.1 Time Period for Collection of Ad verse Events
Adverse events will be collected from t ime of signature of informed consent throughout the 
treatm ent peri od and including the follow -up period through 14 days post dosing (Days 1 
through 15).
All SAEs will be recorded from the time of informed consent through 180 day s post dosing 
(Day s 1 through 181).
5.5.2 Recording of Solicited Symptoms
Solicited symptoms will be reported using the terms as defined in this protocol (Section 5.3). 
Oral therm ometers and safet y assessment worksheets will be distributed to subjects on the day  
of investigational product administration. Beginning on the evening of the day  of 
investigat ional product administration th rough 14 days after receipt of invest igational product 
(Day s 1 through 15), the subject will record on the worksheets his/her temperature and the 
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
37of 74 Template 16.2occurrence of solicited symptoms. Temperatures should be taken at approximately the same 
time each day  (pref erably in the evening); however, if mult iple temperatures are taken during 
a given day , the highest tem perature should be recorded on the worksheet regardless of the 
time of day  taken.
5.5.3 Follow- up of Unresolved Adverse Events
Any AEs that are unresolved at the subject’s last AE assessment in the study are fo llowed up 
by the investigator for as long as medically indicated. MedImmune retains the right to request 
additional information for any  subject wi th ongoing AE(s)/SAE(s) at the end of the study , if 
judged ne cessary .
5.6 Reporting of Serious Adverse Events
All SAEs have to be reported, whether or not considered causally related to the invest igational 
product, or to the study  procedure(s). All SAEs will be recorded in the eCRF.
If any SAE occurs in the course of th e study , then Invest igators or other site personnel inform 
the appropriate Sponsor representative(s) within 1 day ie, immediately but no later than 
24hours  of when he or she beco mes aware of it.
The designated Sponsor study  representative works with the Invest igator to ensure that all the 
necessary  informat ion is provided to the Sponsor Patient Safet y data entry  site wi thin 
1calendar day  of initial receipt for fatal and life threatening events and within 5 calendar days 
of initial receipt for all other S AEs.
For fatal  or life -threatening adverse events where important or relevant informat ion is missing, 
active fo llow-up is undertaken immediately .  Investi gators or other site personnel must inform 
Sponsor study  representatives of any  follow-up inform ation on a previously reported SAE 
within 1 calendar day  ie, immediately but no l ater than 24 hours of when he or she beco mes 
aware of it.
Once the Invest igators or other site personnel indicate an AE is serious in the Electronic Data 
Capture (EDC) sy stem , an au tomated em ail alert is sent to inform the designated Sponsor 
study  representative(s).
If the EDC system is not available, then the Invest igator or other study  site personnel  reports a 
SAE to the appropriate Sponsor study  representati ve by telephone. The Sponsor study  
representative will advise the Invest igator/study  site personnel how to proceed.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
38of 74 Template 16.25.7 Other Events Requiring Immediate Reporting
5.7.1 Overdose ……………………
An overdose is defined as a subject receiving a dose of invest igational product in excess of 
that specified in the Package Insert ( Appendix 3), unless otherwise specified in this protocol.
An overdose with associated AEs is recorded as the AE diag nosis/symptoms on the 
relevant AE m odules in the eCRF and on the Overdose eCRF module.
An overdose without associated symptoms is only  reported on the overdose eCRF 
module. If an overdose on an AstraZeneca/MedImmune study  drug occurs i n the course 
of the s tudy, then the Invest igator or other site personnel inform appropriate Sponsor 
study  representatives immediately, or no later than 24 hours of when he or she becomes 
aware of it.
The designated Sponsor study  representative works with the Invest igator to e nsure that all 
relevant informat ion is provided to the Sponsor’s Patient Safet y data entry  site.
For overdoses associated with a SAE, the standard reporting t imelines apply (see Section 5.6). 
For other overdoses, reporting must occur within 30 day s.
5.7.2 Pregnancy
……….
All pregnancies and outcomes of pregnancies should be reported to the Sponsor.
5.7.2.1 Maternal Exposure
Pregnancy itself is not regarded as an adverse event unles s there is a suspicio n that the 
investigat ional product under study  may have interfered with the effect iveness of a 
contraceptive medicat ion.  Congenital abnormalit ies/bi rth defects and spontaneous 
miscarri ages shoul d be reported and handled as SAEs.  Elec tive abortions without 
complicat ions should not be handled as AEs.  The outcome of all pregnancies (spontaneous 
miscarri age, el ective terminat ion, ectopic pregnancy, normal birth or congenital abnormalit y) 
shoul d be f ollowed up and docum ented even if the s ubject was discont inued from the study.
If any pregnancy  occurs in the course of the study , then the Invest igator or other site personnel 
informs the appropriate Sponsor study  representatives wi thin 1 day, i e, immediately but no 
later than 24 hours of when he or she beco mes aware of it.
The designated sponsor study  representative works with the Invest igator to ensure that all 
relevant informat ion is provided to the Sponsor’s Patient Safet y data entry  site wi thin 1 or 5 
calendar day s for SAEs (see Secti on 5.2) and wi thin 30 days for all other pregnancies.
The same timelines apply when outcome informat ion is available.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
39of 74 Template 16.2The pregnancy reporting module in the eCRF is used to report the pregnancy and the 
pregnancy outcome module is used to report the outcome of the pregnancy .
6 STUDY AND DATA MANAG EMENT
6.1 Training of Study Site Personnel
Before the first subject is entered into the study , a MedImmune representative will review and 
discuss the requirements of the Clinical Study  Protocol  and rel ated docum ents wi th the 
investigat ional staff and also train them in any study -specific procedures and system(s) 
utilized.
The Principal Invest igator will ensure that appropriate training r elevant to the study  is given to 
all of these staff, and that any  new informati on relevant to the perform ance of this study  is 
forwarded to the staff invo lved.
The Principal Invest igator will maintain a record of all individuals invo lved in the study  
(medical, nursing and other staff).
6.2 Monitoring of the Study
During the study , a MedImmune representative will have regular contacts with the study  site, 
including visits to:
Provi de inform ation and support to the invest igator(s)
Confirm that facilit ies remain acceptable
Confirm that the invest igational team  is adhering to the protocol, that data are being 
accurately and timely recorded in the eCRFs, and that study  drug accountabilit y checks 
are being performed
Perform  source data verification (a comparison of t he data in the eCRFs with the subject’s 
medical records at the hospital or practice, and other records relevant to the study ) 
including verificat ion of informed consent of participat ing subjects. This will require 
direct access to all original records for each subject (eg, clinic charts)
The MedImmune representative will be available between visit s if the invest igator(s) or other 
staff at the center needs information and advice about the study  conduct.
6.2.1 Source Data
Refer to the Clinical Study  Agreement for location of  source data.
6.2.2 Study Agreements
The Principal Invest igator at each/the center should comply wit h all the terms, condit ions, and 
obligat ions of the Clinical Study  Agreement, or equivalent, for this study . In the event of any  
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
40of 74 Template 16.2inconsistency between this Clinical Study  Protocol and the Clinical Study  Agreement, the 
terms of Clinical Study  Protocol  shall  prevail wi th respect to the conduct of the study  and the 
treatm ent of subjects and in all other respects, not relat ing to study conduct or treatment o f 
subjects, the terms of the Clinical Study  Agreement shall prevail.
Agreements between MedImmune and the Principal Invest igator must be in place before any 
study -related procedures can take place, or subjects are enrolled.
6.2.3 Archiving of Study Documents
Theinvest igator follows the principles outlined in the Clinical Study Agreement.
6.3 Study Timetable and End of Study
An individual subject will be considered to have completed the study if the subject was 
followed through the last protocol -specified visit/asses sment (including telephone contact), 
regardl ess of the number of doses of invest igational product that was received. 
Subjects will be considered not to have co mpleted the study  if consent was withdrawn or the 
subject was lost to fo llow-up (see Secti on 4.1.5 ).
The end o f the study  (“study  com pletion”) is defined as the date of the last protocol -specified 
visit/assessment (including telephone contact) for the last subject in the study . This date will 
be 180 days after the final subject is entered into the study  (Day  181).
6.4 Data Management 
Data m anagement will be performed by MedImmune Data Management staff according to the 
Data Management Plan .
A Web Based Data Capture system will be used for data collect ion and query  handling. The 
investigator will ensure that data are recorded on the eCRFs as specified in the study  protocol  
and in accordance with the instructions provided.
The invest igator ensures the accuracy , com pleteness, and timeliness of the data recorded and 
of the provisio n of answers to data queries according to the Clinical Study  Agreement. The 
investigator will sign the completed eCRFs. A copy o f the com pleted eCRFs will be archived 
at the stu dy site.
6.5 Medical Monitor Coverage
Each subject will be provided wit h contact information for the principal invest igator. In 
addition, each subject will receive a toll -free number intended to provide the subject’s 
physician access to a medical mo nitor 24 ho urs a day , 7 day s a week in the event of an 
emergent si tuation where the subject’s healt h is deemed to be at risk. In this situation, when a 
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
41of 74 Template 16.2subject presents to a medical facilit y where the treating physician or health care provider 
requi res access to a ph ysician who has knowledge of the invest igational product and the 
clinical study  protocol  and the principal investigator is not available, the treating physician or 
healt h care provider can contact a medical mo nitor through this system, which is managed by  
a third party  vendor.
7 ETHICAL AND REGULATO RY REQUIREMENTS
7.1 Ethical Conduct of the Study
The study  will be perform ed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/Good Clinical Pract ice, and applicable 
regul atory  requi rements.
7.2 Subject Data Protection
The Informed Consent Form will incorporate (or, in so me cases, be acco mpanied by a 
separate document incorporating) wording that complies wit h relevant data protection and 
privacy  legislat ion.
Extra precautions are taken to preserve confident iality and prevent genetic data being linked to 
the identi ty of the subject. In except ional circumstances, however, certain individuals might 
see both the genetic data and the personal ident ifiers of a subject. For example, in the case of a 
medical emergency, a MedImmune Medical Monit or or an invest igator might know a 
subject’s ident ity and also have access to his or her genet ic data. Also Regulatory Authorities 
may require access to the relevant files, though the subject’s medical information and the 
genet ic files would remain physically separate.
7.3 Ethics and Regulatory Review
An IRB/IEC should approve the final study  protocol , including the final versio n of the 
Inform ed Consent Form and any  other written info rmation and/or materials to be provided to 
the subjects. The invest igator will ensure the distribut ion of these documents to the applicable 
IRB/IEC, and to the study  site staff.
The opinio n of the IRB/IEC should be given in writing. The invest igator should submit the 
written approval  to MedImmune before enrolment of any subject into the study . 
The IRB/IEC should approve all advertising used to recruit subjects for the study .
MedImmune should approve any modificat ions to the Informed Consent Fo rm that are needed 
to meet local requi rements.
If required by  local regulat ions, the protocol should be re -approved by the IRB/IEC annually.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
42of 74 Template 16.2Before enrolment of any subject into the study , the final study  protocol , including the final 
versio n of the Inform ed Consent Form , is approved by  the nat ional regulatory  authori ty or a 
notification to the nat ional regulatory  authori ty is done, according to local regulations.
MedImmune will handle the distribut ion of any  of these documents to the national regulatory  
authorities.
MedImmune will provide Regulatory  Authori ties, IRB/IEC and Principal Invest igators with 
safet y updates/reports according to local requirements, including suspected unexpected 
serious adverse reactions, where relevant.
Each Principal Investigator is responsible for providing the IRB/IEC with reports of any 
serious and unexpected adverse drug reactions from any  other study  conducted wi th the 
investigat ional product. MedImmune will provide this informat ion to the Principal 
Invest igator so that he/sh e can meet these reporting requirements.
7.4 Informed Consent
The Principal Invest igator(s) at each center will:
Ensure each subject is given full and adequate oral and written information about the 
nature, purpose, possible risk and benefit of the study
Ensur e each subject is notified that they  are f ree to discont inue from the study  at any  time
Ensure that each subject is given the opportunit y to ask questi ons and all owed time to 
consider the information provided
Ensure each subject provides signed and dated i nformed consent before conducting any 
procedure specifically  for the study
Ensure the original, signed Informed Consent Form(s) is/are stored in the Invest igator’s 
Study  File
Ensure a copy  of the signed Informed Consent Form is given to the subject
Ensure that any  incentives for subjects who participate in the study  as well  as any  
provi sions for subjects harmed as a consequence of study  parti cipat ion are described in 
the Informed Consent Form that is approved by an IRB/IEC
7.5 Changes to the Protocol and Infor med Consent Form
Study  procedures will not be changed without the mutual agreement of the Coordinat ing 
Invest igator, the Principal Investigator, and MedImmune.
If there are any substant ial changes to the study  protocol , then these changes will be 
docum ented in a study  protocol  amendment and where required in a new versio n of the study  
protocol .
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
43of 74 Template 16.2The am endment i s to be approved by  the rel evant IRB/IEC and if applicable, also the national 
regul atory  authori ty approval , before implementation. Local  requi rements are to be fo llowed 
for revised protocols.
MedImmune will distribute any  subsequent am endments and new versio ns of the protocol to 
each Principal Invest igator(s). For distribut ion to IRB/IEC see Section 7.3.
If a protocol amendment requires a change to a site’s Informed Consent Form, MedImmune 
and the site’s IRB/IEC are to approve the revised Informed Consent Form before the revised 
form is used . 
If local regulat ions requi re, any  administrative change will be communicated to or approved 
by each IRB/IEC.
7.6 Audits and Inspections
Authori zed representatives of MedImmune, a regulatory  authori ty, or an IRB/IEC m ay 
perform  audi ts or i nspect ions at the c enter, including source data verificat ion. The purpose of 
an audit or inspect ion is to sy stematically and independent ly examine all study- related 
activit ies and documents, to assess whether these activit ies were conducted and data were 
recorded, analyzed, and accurately  reported according to the protocol, Good Clinical Pract ice, 
guidelines o f the ICH, and any  applicable regulatory  requi rements. The invest igator will 
contact MedImmune immediately if contacted by  a regul atory  agency  about an inspect ion at 
thesite.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
44of 74 Template 16.28 REFERENCES
Centers for Disease Control and Prevent ion (CDC), 2016. Select ing viruses for the seasonal 
influenza vaccine. Available fro m: https://www.cdc.gov/flu/about/season/vaccine -
select ion.htm.
Chan IS. Exact tests of equivalence and efficacy wit h a non -zero l ower bound for com parat ive 
studi es. Stat Med. 1998;17:1403 -13.
Chan IS, Zhang Z. Test -based exact confidence int ervals for the difference of two bino mial 
proporti ons. Bi ometrics. 1999;55:1202 -9.
Maassab HF. Plaque format ion of influenza virus at 25 degrees C. Nature. 1968;219:645 -6.
Maassab H, DeBorde D, Donabedian A, Smitka C. Development of co ld-adapted m aster 
strains for ty pe-B influenza virus vaccines. In: Lerner R, Chanock R, Brown, F, editors. 
Vaccines Vo l 85. Col d Spring Harbor Laborato ry. 1985;p. 327 -32.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
45of 74 Template 16.2Appendix 1Signature of Principal Investigator
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
46of 74 Template 16.2Signature of Principal Investigator
A Phase 4, Rando mized, Double -blind, Pl acebo -controlled Study  to Eval uate the Safet y of 2
New 6:2 Influenza Virus Reassortant sin Adults 
I, the undersig ned, have reviewed this protocol, and I agree to conduct this protocol in 
accordance with ethical principles that have their origin in the Declarat ion of Helsinki and are 
consistent with the Internat ional Council for Harmonisation (ICH) guidelines on Good 
Clinical Practice (GCP), any  applicable l aws and requi rements, and any condit ions required 
by a regul atory  authori ty and/or Institutional Review Board/Independent Ethics Co mmittee 
(IRB/IEC). 
I understand that the protocol may not be modified without written approval  of the sponsor. 
All changes to the protocol must be submitted to the applicable regulatory  authori ty and 
IRB/IEC, and must be approved by  the IRB/IEC prior to implementation except when 
necessary  to eliminate immediate hazards to the subje cts or when the change(s), as deemed by  
the sponsor, invo lves only logist ical or administrative changes. Documentation of IRB/IEC 
approval  must be sent to the sponsor immediately  upon recei pt.
Signature and date: 
Nam e and ti tle:  
Address including postal code: 
  
Telephone number: 
Site/Center Number (if available)
This document contains confidential information, which should not be copied, referred to, released, or published 
without written approval from MedImmune or AstraZeneca. Investigators are cautioned that the information in 
this protocol may be subject to change and revision.
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
47of 74 Template 16.2Appendix 2Additional Safety Guidance
Assessment of Severity
Assessme nt of severi ty is one of the responsibilit ies of the invest igator in the evaluation o f 
AEs and SAEs. The determinat ion of severit y should be m ade by  the invest igator based upon 
medical judgment and the severit y categori es of  Grade 1 to 5 as defined below.
Grade 1 (mild) An event that is usually transient and may require only  minimal  
treatm ent or therapeutic intervent ion. The event does not 
generally interfere with usual act ivities of daily living.
Grade 2 (m oderate) An event that is usually alleviated with additional specific 
therapeuti c intervent ion. The event interferes with usual 
activit ies o f daily living, causing disco mfort but poses no 
significant or permanent risk of harm to the subject.
Grade 3 (severe) An event that requires intensive therapeutic in terventi on. The 
event interrupts usual act ivities of daily living, or significantly 
affects the clinical status of the subject.
Grade 4 (life threatening) An event, and/or its immediate sequelae, that is associated with 
an imminent risk of death or with ph ysical or mental disabilit ies 
that affect or limit the abilit y of the subject to perform activit ies 
of daily living (eat ing, ambulation, toilet ing, etc).
Grade 5 (fatal) Death (loss of life) as a result of an event.
It is important to dist inguish between serious cri teria and severit y of an AE. Severit y is a 
measure of intensit y whereas seri ousness is defined by  the cri teria in Sect ion5.2. A Grade 3 
AE need not necessarily be considered an SAE. For example, a Grade 3 headache that persists 
for several  hours may  not meet the regulatory defini tion of an SAE and woul d be considered a 
nonseri ous event, whereas a Grade 2 seizure resul ting in a hospital a dmissi on woul d be 
considered an SAE.
Assessment of Relationship
Relationship to Invest igational Product
The invest igator is required to provide an assessment of relat ionship of AEs and SAEs to the 
investigat ional product.
An event will be considered “not r elated” to use of the investigational product if any of the 
following tests are met:
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
48of 74 Template 16.2An unreasonable temporal relat ionship between administration of the invest igational 
product and the onset of the event (eg, the event occurred either before, or too long after, 
administration of the investigat ional product for it to be considered product- related)
A causal relat ionship between the investigational product and the event is bio logically  
implausible (eg, death as a passenger in an automobile accident)
A clearly more likely alternative explanation for the event is present (eg, ty pical adverse 
reacti on to a concomitant drug and/or ty pical disease -related event)
Individual AE/SAE reports will be considered “related” to use of the investigational product if 
the “no t related” cri teria are not m et. 
“Related” implies that the event is considered to be “associated with the use of the drug” 
meaning that there is “a reasonable possibilit y” that the event may  have been caused by  the 
product under invest igation (ie, there are facts, evidence, or arguments to suggest possible 
causat ion).
Relationship to Protocol Procedures
The invest igator is also required to provide an assessment of relat ionship of SAEs to protocol 
procedures on the SAE Report Form. This includes nontreatme nt-emergent SAEs (ie, SAEs 
that occur prior to the administration o f investigational product) as well as treatment -emergent 
SAEs. A protocol -related SAE m ay occur as a result of a procedure or intervent ion required 
during the study  (eg, bl ood collect ion, washout of an exist ing medicat ion). The fo llowing 
guidelines shoul d be used by  investi gators to assess the relat ionship of SAEs to the protocol:
Protocol  related: The event occurred due to a procedure/intervention that was described 
in the protocol for whic h there i s no al ternat ive et iology  present in the 
subject’s medical record.
Not protocol related: The event is related to an etio logy other than the procedure/ 
intervent ion that was described in the protocol (the alternative et iology 
must be documented in the study  subject’s m edical record).
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
49of 74 Template 16.2Appendix 3FluMist®Quadrivalent Package Insert 
MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
50of 74 Template 16.2   

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
51of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
52of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
53of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
54of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
55of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
56of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
57of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
58of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
59of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
60of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
61of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
62of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
63of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
64of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
65of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
66of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
67of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
68of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
69of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
70of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
71of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
72of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
73of 74 Template 16.2

MedImmune Protocol D2560C0001 5
MEDI3250 (FluMist®Quad rivalent) 27Mar2018; Final
74of 74 Template 16.2

SIGNATURE PAGE
This is a representation of an electronic record that was signed
electronically and this page is the manifestation of the electronic signature
Document Name: d2560c00015-csp-v1
Document Title: d2560c00015 clinical study protocol version 1
Document ID: Doc ID-003765938
Version Label: 3.0 CURRENT LATEST APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)Signed by Meaning of Signature
06-Apr-2018 13:21 UTC Author Approval
05-Apr-2018 18:45 UTC Author Approval
05-Apr-2018 19:38 UTC Author Approval
05-Apr-2018 18:40 UTC Author Approval
Notes: (1) Document details as stored in ANGEL, an AstraZeneca document management system.
